Influenza A virus subtype H1N1 clinical trials
How each study uses influenza A virus subtype H1N1 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2009 (16)
| Year | Studies |
|---|---|
| 2009 | 16 |
| 2010 | 3 |
| 2012 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 17
National Institute of Allergy and Infectious Diseases (NIAID) (9) · University of Rochester (2) · Adimmune Corporation (2) · French National Agency for Research on AIDS and Viral Hepatitis (1) · Imperial College London (1) · Francis Corazza (1) · GlaxoSmithKline (1) · Chiltern Pesquisa Clinica Ltda (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses influenza A virus subtype H1N1 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 22
- Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)CompletedPhase 2French National Agency for Research on AIDS and Viral HepatitisNCT01008813Written as adjuvanted A(H1N1)v influenza vaccineHow we know
- Cell Mediated Immunity Against RSV and Influenza in a Human Experimental ChallengeCompletedNot applicableImperial College LondonNCT02755948Written as Influenza A/California/04/2009-likw (H1N1)How we know
- Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant WomenCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00992017Written as Influenza A (H1N1) monovalent vaccineHow we know
- Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and YouthCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00992836Written as Influenza A (H1N1) 2009 monovalent vaccineHow we know
- Monocytic Expression of Heme Oxidase-1 (HO-1) in Sickle Cell Patients and Correlation With the Humoral Immune Response to Vaccine and With Allo-immunization.CompletedNot applicableFrancis CorazzaNCT03111589Written as Inactivated influenza A (H1N1) virus vaccineHow we know
- CSL H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly PopulationsWithdrawnPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00964951Written as Inactivated H1N1 VaccineHow we know
- Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese ChildrenCompletedPhase 2GlaxoSmithKlineNCT01001169Written as GSK Biologicals' Pandemic influenza (H1N1) candidate vaccine (GSK2340274A)How we know
- Effect of Age and Prior Immunity on Response to H1N1 Vaccines in ChildrenWithdrawnPhase 4University of RochesterNCT01097941Written as Influenza A (H1N1) 2009 Monovalent VaccineHow we know
- Immunologic Response to Inactivated Vaccine for Novel H1N1 VirusCompletedNot applicableUniversity of RochesterNCT01023711Written as Inactivated H1N1 vaccineHow we know
- Novartis H1N1 Vaccine in Pregnant WomenCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00992719Written as Inactivated H1N1 VaccineHow we know
- Sanofi Pasteur, TIV + H1N1, Pediatric PopulationCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00943202Written as Inactivated H1N1 VaccineHow we know
- H1N1 Vaccine in Pregnant WomenCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00963430Written as Inactivated H1N1 VaccineHow we know
- Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly PopulationsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00943631Written as Inactivated H1N1 VaccineHow we know
- CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly PopulationsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00943488Written as Inactivated H1N1 VaccineHow we know
- Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid TumorsCompletedPhase 3Chiltern Pesquisa Clinica LtdaNCT01031719Written as adjuvanted A(H1N1) influenza vaccineHow we know
- Phase I/II Safety and Immunogenicity of Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1) in Healthy ThaisCompletedPhase 1/2Mahidol UniversityNCT01666262Written as Vaccine A/17/CA/2009/38 (H1N1)How we know
- Sanofi H1N1 + TIV - Adults and ElderlyCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00943878Written as Inactivated H1N1 VaccineHow we know
- Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1WithdrawnPhase 2Instituto Nacional de Salud Publica, MexicoNCT00989274Written as Vaccine Sanofi A(H1N1) 15 ug & trivalentHow we know
- Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric PopulationCompletedNot applicableAdimmune CorporationNCT01007201Written as Influenza A (H1N1) 2009 monovalent vaccine, inactivatedHow we know
- Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and EldersCompletedNot applicableAdimmune CorporationNCT01003145Written as Influenza A (H1N1) 2009 monovalent vaccine, inactivatedHow we know
See all 22 studies that test influenza A virus subtype H1N1 →
Given beside what is tested · 1 — influenza A virus subtype H1N1 is usual care or a partner of the new treatment
Codes
What other systems call influenza A virus subtype H1N1 · ClinicalTrials.gg INT015776
- Wikidata Q161393influenza A virus subtype H1N1One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| Wikidata | Q161393 | influenza A virus subtype H1N1 | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.